NEW YORK (GenomeWeb News) ─ Myriad Genetics has submitted to the US Food and Drug Administration the first module of its premarket approval application for BRACAnalysis as a companion test for AstraZeneca's breast cancer PARP inhibitor olaparib.
Registering provides access to this and other free content.
Already have an account?Login Now.
In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.
A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.
Researchers report that paternally inherited genes are more likely to be expressed in mice.
In PNAS this week: Akt3 amplification in glioma progression, Tibetan Plateau frog genome, and more.